The effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters

Basit Öğe Kaydı
dc.authorscopusid57200105522
dc.authorscopusid57200105523
dc.authorscopusid14520105500
dc.authorscopusid56611865100
dc.authorscopusid57201272074
dc.authorscopusid35078444700
dc.contributor.authorBilir, Bülent
dc.contributor.authorEkiz Bilir, Betül
dc.contributor.authorTakir, M.
dc.contributor.authorSertbaş, Y.
dc.contributor.authorAkıncı, C.M.
dc.contributor.authorÇiftçi, H.
dc.date.accessioned2022-05-11T14:39:53Z
dc.date.available2022-05-11T14:39:53Z
dc.date.issued2015
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThe effect of ezetimibe monothrepy on decreasing lipid molecules has been widely studied in the literature so far, but scarce number of clinical studies have evaluated the effect of this pharmacological agent on lipoprotein-(a). In our study, we aimed to evaluate the effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters with clinical aspects. Ezetimibe monotherapy for three months was used for the hyperlipidemic patients admitted to our internal medicine outpatient clinic. Lipoprotein-(a) total cholesterol, low-density lipoprotein, very-low-density lipoprotein, high-density lipoprotein, and triglyceride levels before and after ezetimibe therapy were subjected to biochemical analysis. In addition to descriptive statistics of data, paired-t-test and Pearson Correlation analysis were used. All results were evaluated within 95% confidence interval and considered as statistically siginificant if p values were lower than 0.05. After treatment lipoprotein-(a), total cholesterol, and LDL-cholesterol levels decreased but the changes in very low-density lipoprotein, high-density lipoprotein, and triglyceride levels were not statistically siginificant (p>0.05). In the treatment of hyperlipidemia, ezetimibe can be an adjunct to other antihyperlipidemic drugs or an alternative monotherapy. © 2015, Logos Medical Publishing. All rights reserved.
dc.identifier.doi10.5222/MMJ.2015.083
dc.identifier.endpage88
dc.identifier.issn2149-2042
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85044137843
dc.identifier.scopusqualityQ4
dc.identifier.startpage83
dc.identifier.urihttps://doi.org/10.5222/MMJ.2015.083
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8781
dc.identifier.volume30
dc.indekslendigikaynakScopus
dc.institutionauthorBilir, Bülent
dc.language.isotr
dc.publisherLogos Medical Publishing
dc.relation.ispartofMedeniyet Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAtherosclerosis
dc.subjectEzetimibe
dc.subjectLipoprotein-(a)
dc.titleThe effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters
dc.title.alternativeEzetimib monoterapisinin lipoprotein (a) ve diğer lipid parametreleri üzerine etkisi]
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu